News >

Ibrutinib Combo Improves PFS in Waldenstrom Macroglobulinemia

Jason M. Broderick @jasoncology
Published: Tuesday, Dec 05, 2017

Meletios Dimopoulos, MD

Meletios Dimopoulos, MD
The combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) improved progression-free survival (PFS) versus rituximab alone in patients with Waldenström macroglobulinemia enrolled in the phase III iNNOVATE (PCYC-1127) trial.

The FDA approved single-agent ibrutinib for patients with WM in January 2015, based on results from a phase II study.
Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology. 2017;18(2):241-250. doi:10.1016/s1470-2045(16)30632-5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x